369 related articles for article (PubMed ID: 22359151)
41. Identification and treatment of cervical and oromandibular dystonia in acutely brain-injured patients.
Lo SE; Rosengart AJ; Novakovic RL; Kang UJ; Shah DN; Khan MA; Dalvi A; Goldenberg FD; Macdonald RL; Frank JI
Neurocrit Care; 2005; 3(2):139-45. PubMed ID: 16174883
[TBL] [Abstract][Full Text] [Related]
42. Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia.
Swope D; Barbano R
Neurol Clin; 2008 May; 26 Suppl 1():54-65. PubMed ID: 18603168
[TBL] [Abstract][Full Text] [Related]
43. Botulinum toxin in the treatment of rare head and neck pain syndromes: a systematic review of the literature.
Sycha T; Kranz G; Auff E; Schnider P
J Neurol; 2004 Feb; 251 Suppl 1():I19-30. PubMed ID: 14991339
[TBL] [Abstract][Full Text] [Related]
44. KinesioTaping after botulinum toxin type A for cervical dystonia in adult patients.
Dec-Ćwiek M; Porębska K; Sawczyńska K; Kubala M; Witkowska M; Zmijewska K; Antczak J; Pera J
Brain Behav; 2022 Apr; 12(4):e2541. PubMed ID: 35238494
[TBL] [Abstract][Full Text] [Related]
45. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
Brin MF; Lew MF; Adler CH; Comella CL; Factor SA; Jankovic J; O'Brien C; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
Neurology; 1999 Oct; 53(7):1431-8. PubMed ID: 10534247
[TBL] [Abstract][Full Text] [Related]
46. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248
[TBL] [Abstract][Full Text] [Related]
47. [Botulinum toxin in the treatment of focal dystonias: own experience with botulinum toxin].
Stefanoff P; Kiliszek M; Friedman A
Neurol Neurochir Pol; 2000; 34(1):61-70. PubMed ID: 10849905
[TBL] [Abstract][Full Text] [Related]
48. Temporomandibular disorders in patients with craniocervical dystonia.
Costa AL; Campos LS; França MC; D'Abreu A
Arq Neuropsiquiatr; 2011 Dec; 69(6):896-9. PubMed ID: 22297875
[TBL] [Abstract][Full Text] [Related]
49. Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value.
Zoons E; Dijkgraaf MG; Dijk JM; van Schaik IN; Tijssen MA
J Neurol; 2012 Dec; 259(12):2519-26. PubMed ID: 22552527
[TBL] [Abstract][Full Text] [Related]
50. Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up.
Ramirez-Castaneda J; Jankovic J
Toxicon; 2014 Nov; 90():344-8. PubMed ID: 25130293
[TBL] [Abstract][Full Text] [Related]
51. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.
Costa J; Borges A; Espírito-Santo C; Ferreira J; Coelho M; Moore P; Sampaio C
Cochrane Database Syst Rev; 2005 Jan; (1):CD004314. PubMed ID: 15674940
[TBL] [Abstract][Full Text] [Related]
52. Botulinum toxin therapy of dystonia.
Dressler D; Adib Saberi F; Rosales RL
J Neural Transm (Vienna); 2021 Apr; 128(4):531-537. PubMed ID: 33125571
[TBL] [Abstract][Full Text] [Related]
53. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.
Albrecht P; Jansen A; Lee JI; Moll M; Ringelstein M; Rosenthal D; Bigalke H; Aktas O; Hartung HP; Hefter H
Neurology; 2019 Jan; 92(1):e48-e54. PubMed ID: 30464031
[TBL] [Abstract][Full Text] [Related]
54. Focal dystonia: the role of botulinum toxin.
Tintner R; Jankovic J
Curr Neurol Neurosci Rep; 2001 Jul; 1(4):337-45. PubMed ID: 11898539
[TBL] [Abstract][Full Text] [Related]
55. Botulinum toxin and conservative treatment strategies in people with cervical dystonia: an online survey.
Boyce MJ; McCambridge AB; Bradnam LV; Canning CG; De Oliveira CQ; Verhagen AP
J Neural Transm (Vienna); 2024 Jan; 131(1):43-51. PubMed ID: 37831150
[TBL] [Abstract][Full Text] [Related]
56. Role of botulinum toxin in the treatment of cervical dystonia.
Molho E; Jankovic J; Lew M
Neurol Clin; 2008 May; 26 Suppl 1():43-53. PubMed ID: 18603167
[No Abstract] [Full Text] [Related]
57. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia.
Figgitt DP; Noble S
Drugs; 2002; 62(4):705-22. PubMed ID: 11893235
[TBL] [Abstract][Full Text] [Related]
58. Reply: Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial.
Mueller J
Mov Disord; 2009 May; 24(7):1098-9; author reply 1100. PubMed ID: 18942082
[No Abstract] [Full Text] [Related]
59. Pharmacotherapy with botulinum toxin: harnessing nature's most potent neurotoxin.
Bell MS; Vermeulen LC; Sperling KB
Pharmacotherapy; 2000 Sep; 20(9):1079-91. PubMed ID: 10999501
[TBL] [Abstract][Full Text] [Related]
60. Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?
Duarte GS; Rodrigues FB; Ferreira JJ; Costa J
Parkinsonism Relat Disord; 2018 Nov; 56():16-19. PubMed ID: 29910156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
